The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.
 
Yutaka Yamamoto
Honoraria - Chugai Pharma
Consulting or Advisory Role - Novartis
Research Funding - Taiho Pharmaceutical
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Eisai
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; Novartis
Research Funding - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Novartis; Pfizer
 
Takayuki Ueno
No Relationships to Disclose
 
Masahiro Kashiwaba
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Pfizer; Sanofi
Research Funding - Chugai Pharma
 
Naruto Taira
Research Funding - AstraZeneca Japan
 
Masato Takahashi
No Relationships to Disclose
 
Hiroshi Tada
No Relationships to Disclose
 
Koichiro Tsugawa
No Relationships to Disclose
 
Tatsuya Toyama
Research Funding - Daiichi Sankyo; Novartis; Takeda
 
Naoki Niikura
No Relationships to Disclose
 
Fumikata Hara
Research Funding - Chugai Pharma; Eisai
 
Tomomi Fujisawa
No Relationships to Disclose
 
Tetsuhiro Yoshinami
Honoraria - Chugai Pharma
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Novartis; Pfizer
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Toshimi Takano
Honoraria - Daiichi Sankyo; Kyowa Hakko Kirin
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin
Research Funding - AstraZeneca Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer
 
Satoshi Morita
Honoraria - Chugai Pharma
Consulting or Advisory Role - Chugai Pharma
 
Masakazu Toi
Research Funding - Chugai Pharma
 
Shinji Ohno
Honoraria - Chugai Pharma